Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

Exclusion Criteria

• •\<18 years
• •non-Dutch speaking
• •recent (\<6 months) major bleeds according with the International Society on Thrombosis and Haemostasis definition of major bleeding in non-surgical patients (20)
• •creatinine clearance of \< 15 mL/min or dialysis dependent
• •liver failure classified as Child Pugh C
• •total bilirubin ≥ 1.77 mg/dL (= 1,5 x upper limit of normal)
• •presence of coagulopathy and a clinically relevant bleeding risk
• •pregnancy or lactation
• •concomitant intake of strong combined inhibitors of CYP3A4 and P-gp
• •participation in a recent (\<1 month) trial with an investigational product
• •recent (\<6 months) gastrointestinal surgery
• •gastrointestinal mucosal disease interfering with absorption (e.g. radio-enteritis, inflammatory bowel disease, celiac disease, …)
• •gastrointestinal fistulae
• •SBS with intestinal failure resulting from gastric bypass surgery
• •\<18 years
• •non-Dutch speaking
• •recent (\<6 months) major bleeds according with the International Society on Thrombosis and Haemostasis definition of major bleeding in non-surgical patients (20)
• •creatinine clearance of \< 15 mL/min or dialysis dependent
• •liver failure classified as Child Pugh C
• •total bilirubin ≥ 1.77 mg/dL (= 1,5 x upper limit of normal)
• •presence of coagulopathy and a clinically relevant bleeding risk
• •pregnancy or lactation
• •concomitant intake of strong combined inhibitors of CYP3A4 and P-gp
• •use of prokinetics, antimotility drugs or opioids
• •participation in a recent (\<1 month) trial with an investigational product